Next Generation Diabetes Therapy and Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas), By Indication (Type 1 diabetes, Type 2 diabetes), By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare), By Region and Competition
Global Next Generation Diabetes Therapy and Drug Delivery Market has valued at USD 22.25 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2028. Diabetes is a chronic disease that affects millions of people worldwide, and its management requires ongoing efforts to control blood sugar levels and prevent complications. The field of diabetes therapy and drug delivery has seen remarkable progress in recent years, thanks to innovative research and technology. The global next-generation diabetes therapy and drug delivery market is on the cusp of transformative change, offering new hope for individuals living with diabetes. Diabetes is a metabolic disorder characterized by elevated blood sugar levels, resulting from the body's inability to produce enough insulin or effectively utilize the insulin it produces. It can lead to serious complications such as heart disease, kidney problems, vision loss, and neuropathy if not properly managed. Effective diabetes therapy and drug delivery are essential to help patients lead healthier lives.
The global market for next-generation diabetes therapy and drug delivery is undergoing rapid expansion. Several factors contribute to this growth, including a rising global incidence of diabetes, technological advancements, and increased awareness about the importance of diabetes management. One of the key drivers of innovation in diabetes therapy and drug delivery is the advancement of technology. Continuous glucose monitoring (CGM) systems, insulin pumps, and smart insulin pens are some examples of cutting-edge technologies that have revolutionized the way patients manage their diabetes. These devices provide real-time data and automate insulin delivery, improving precision and convenience.
Key Market Drivers
Growing Diabetes Epidemic is Driving the Global Next Generation Diabetes Therapy and Drug Delivery Market
The global diabetes epidemic is a major public health concern, affecting individuals of all ages and backgrounds. According to the International Diabetes Federation (IDF), in 2019, there were approximately 463 million adults living with diabetes, and this number is projected to rise to 700 million by 2045 if current trends persist. The majority of diabetes cases are of the type 2 variety, which is closely linked to lifestyle factors such as poor diet and physical inactivity. The impact of diabetes goes beyond health concerns, as it places a significant economic burden on healthcare systems. Diabetes-related medical expenses and lost productivity have a substantial economic cost, both on a global and individual scale. Recognizing the dire need for more effective and patient-friendly treatments, the Next Generation Diabetes Therapy and Drug Delivery market has witnessed significant growth. Innovations in this field aim to address the unique challenges faced by people with diabetes, ultimately leading to better disease management and improved quality of life.
Traditional insulin injections are often inconvenient and painful for individuals with diabetes. The development of advanced insulin delivery systems, such as insulin pumps and continuous glucose monitoring devices, has revolutionized diabetes management. These devices offer precise insulin delivery, reduce the risk of hypoglycemia, and provide real-time glucose monitoring, thus improving overall glycemic control. Researchers have been working on developing an oral insulin delivery method, which would eliminate the need for injections. This technology has the potential to significantly improve patient adherence to treatment regimens. The concept of an artificial pancreas is a game-changer in diabetes therapy. It combines continuous glucose monitoring with automated insulin delivery, creating a closed-loop system that can respond to fluctuations in blood glucose levels in real-time. Such innovations offer the promise of better blood sugar control and fewer diabetes-related complications. Advances in genomics and personalized medicine have enabled the development of diabetes treatments tailored to an individual's genetic makeup. These treatments may prove to be more effective and have fewer side effects than traditional therapies. Telemedicine and digital health solutions have become integral in diabetes management. They provide remote monitoring and support, allowing healthcare professionals to track patients' progress and adjust treatment plans as necessary.
The global Next Generation Diabetes Therapy and Drug Delivery market is expected to grow significantly in the coming years. Factors such as the increasing prevalence of diabetes, the need for more patient-friendly treatment options, and ongoing research and development in the field of diabetes management contribute to this growth. The market is also likely to witness collaborations between pharmaceutical companies, medical device manufacturers, and digital health companies to offer comprehensive solutions for diabetes care. Furthermore, regulatory bodies around the world are increasingly supportive of innovation in diabetes management, streamlining the approval process for new therapies and devices. This has created a favorable environment for companies seeking to bring new products to the market.
Rising Healthcare Expenditure is Driving the Global Next Generation Diabetes Therapy and Drug Delivery Market
The rising healthcare expenditure worldwide, coupled with the growing prevalence of diabetes, has created a strong impetus for the development and adoption of next-generation diabetes therapy and drug delivery solutions. These innovative approaches offer the potential to reduce the economic and human toll of diabetes, improve patient outcomes, and enhance the sustainability of healthcare systems. As research and development in this field continue to progress, the future holds promise for individuals living with diabetes and those dedicated to providing them with the best care possible.
The growth of the global next generation diabetes therapy and drug delivery market is closely tied to the increasing healthcare expenditure seen in many countries. As the number of people living with diabetes continues to grow, healthcare systems are under increasing pressure to provide effective and cost-efficient solutions. Investing in next-generation therapies and drug delivery systems is seen as a way to address this challenge. Diabetes imposes a significant economic burden on both individuals and healthcare systems. The cost of treating diabetes-related complications, hospitalizations, and medications is substantial. Innovations in diabetes management can help reduce these costs and improve overall healthcare sustainability. The shift towards patient-centered care and the demand for improved quality of life has led to the development of next-generation therapies that focus on patient convenience, adherence, and outcomes. Advances in medical technology, data analytics, and artificial intelligence are driving the development of innovative solutions in diabetes management. These technologies not only improve patient care but also contribute to healthcare system efficiency.
Key Market Challenges
Regulatory and Approval Processes
One of the primary challenges in the global diabetes therapy market is the stringent regulatory environment. Developing new therapies and drug delivery methods requires extensive testing, clinical trials, and rigorous safety and efficacy assessments. Obtaining regulatory approval can be a long and costly process, often taking years. This can discourage smaller companies with innovative solutions from entering the market, as they may not have the resources to navigate the regulatory hurdles effectively.
Cost of Innovation
Innovation in diabetes therapy and drug delivery comes at a high cost. Developing and testing new technologies, medications, and delivery methods requires substantial investments in research and development. Many innovative therapies and drug delivery systems remain out of reach for patients due to their high price points. This cost can be a significant barrier to access for individuals with diabetes, particularly in low-income and underprivileged regions.
Patient Adherence
Patient adherence to diabetes therapies and drug delivery methods is a persistent challenge. Even with the introduction of innovative options, patients may struggle to follow their treatment regimens. This non-adherence can lead to suboptimal health outcomes and increased healthcare costs. There is a need for greater patient education, support, and user-friendly therapies to enhance adherence.
Integration of Digital Health Solutions
The integration of digital health solutions and technology into diabetes therapy and drug delivery is a promising avenue, but it comes with its own set of challenges. Ensuring data privacy and security while using apps, wearable devices, and telehealth platforms is critical. Additionally, not all patients have access to smartphones or the internet, potentially leaving some individuals with diabetes at a disadvantage.
Tailoring Therapies to Individual Needs
Diabetes is a highly individualized condition. What works for one patient may not work for another. Personalized medicine has the potential to revolutionize diabetes management, but developing tailored therapies and drug delivery methods can be complex and costly. It requires a deep understanding of a patient's genetic, metabolic, and lifestyle factors, which is not always feasible in routine clinical practice.
Global Disparities
Access to next-generation diabetes therapies and drug delivery methods is not evenly distributed around the world. High-income countries often have better access to cutting-edge treatments, while low and middle-income nations may face limited resources and infrastructure. Addressing these global disparities is a significant challenge in ensuring equitable diabetes care.
Competition and Market Saturation
As the global diabetes therapy and drug delivery market becomes more competitive, companies must continually innovate to stay ahead. However, the market may become saturated with similar products, making it difficult for newcomers to gain a foothold. Additionally, competitive pricing can lead to price wars that negatively impact profit margins.
Key Market Trends
Technological Advancements
Diabetes has emerged as a global health crisis, affecting millions of people worldwide. As the prevalence of diabetes continues to rise, so does the demand for innovative and effective treatments. Technological advancements are playing a pivotal role in shaping the next generation of diabetes therapy and drug delivery solutions, driving the growth of the global diabetes market. Continuous Glucose Monitoring (CGM) Systems have revolutionized diabetes management by providing real-time glucose level data. These devices, often paired with smartphone apps, enable patients and healthcare providers to monitor and adjust insulin levels more accurately. The development of smaller, more comfortable sensors and improved data accuracy has made CGM a game-changer in diabetes therapy. Artificial pancreas systems, also known as closed-loop systems, combine CGM technology with insulin pumps. These devices automatically adjust insulin delivery based on real-time glucose data, reducing the burden on patients and improving blood sugar control. The FDA's approval of such systems has further advanced the adoption of this technology. Traditional insulin pens and pumps have evolved into smart, connected devices that track insulin doses and provide reminders for patients. They allow healthcare providers to remotely monitor and adjust insulin regimens, enhancing patient care and compliance.
Smartphone apps and digital platforms provide patients with tools for tracking their glucose levels, medications, and dietary habits. These platforms also offer educational resources and connect patients with healthcare professionals, promoting self-management and facilitating more personalized treatment plans. Technological advancements have also led to the development of innovative drug delivery systems, such as inhalable insulin and smart patches. These solutions aim to improve the ease of insulin administration and reduce the stigma associated with diabetes treatment.
The convergence of these technological advancements has resulted in a booming market for next-generation diabetes therapy and drug delivery solutions. The global diabetes care devices market was valued at approximately $20 billion in 2020 and is expected to experience robust growth in the coming years. This growth is driven by the increasing prevalence of diabetes, rising patient awareness, and the demand for more convenient and efficient treatment options. Moreover, ongoing research and development in the field of diabetes technology are fueling innovation. Pharmaceutical and medical device companies are investing heavily in improving existing technologies and developing new solutions, which further propel the market's expansion.
Segmental Insights
Product Type Insights
Based on the category of Product Type, CGM Systems emerged as the dominant player in the global market for Next Generation Diabetes Therapy and Drug Delivery in 2022 Continuous Glucose Monitoring (CGM) systems are at the forefront of the next generation of diabetes therapy and drug delivery. These systems use tiny sensors inserted under the skin to measure glucose levels in the interstitial fluid continuously. The data collected is transmitted wirelessly to a receiver or smartphone, providing real-time glucose information, trends, and alerts. CGM systems offer immediate feedback on glucose levels, allowing individuals with diabetes to make informed decisions about their food intake, insulin dosages, and lifestyle choices. CGM systems help individuals maintain target glucose levels, reducing the risk of hypoglycemia and hyperglycemia, which can have severe consequences. These systems provide valuable insights into a person's unique glucose patterns, enabling healthcare professionals to create tailored treatment plans. CGM systems reduce the need for frequent fingerstick tests and simplify the diabetes management process, leading to a better quality of life for patients. CGM technology has continued to evolve, with each new generation of devices becoming more accurate, comfortable, and user-friendly. As these systems become more sophisticated, they offer more than just glucose data. Some CGM devices now provide predictive algorithms and even insulin dosing recommendations.
End user Insights
The Diagnostic/Clinics segment is projected to experience rapid growth during the forecast period. The diagnostic/clinics segment encompasses a wide range of services and tools designed to improve the diagnosis of diabetes and its complications. Early diagnosis is crucial in effective diabetes management, and the segment offers advanced screening tests, point-of-care diagnostics, and genetic testing, aiding in the timely identification of the condition. Clinics equipped with the latest diagnostic technologies can provide a more personalized approach to diabetes management. With the help of advanced diagnostics, healthcare professionals can tailor treatment plans to individual patients, resulting in better glycemic control and patient satisfaction.
Regional Insights
North America emerged as the dominant player in the global Next Generation Diabetes Therapy and Drug Delivery market in 2022, holding the largest market share in terms of value. North America boasts a well-established pharmaceutical and biotechnology sector, with numerous companies dedicated to diabetes research. Leading players, such as Eli Lilly, Novo Nordisk, and Johnson & Johnson, have their headquarters or major operations in the United States. This concentration of industry giants ensures a continuous stream of innovation and investment in diabetes care. North American institutions and universities conduct groundbreaking research in the field of diabetes, which often leads to the development of innovative therapies and drug delivery systems. Collaborations between academia and the private sector are commonplace, facilitating the translation of research findings into practical solutions. The regulatory framework in North America is stringent, ensuring that new therapies and drug delivery methods meet the highest safety and efficacy standards. This environment encourages the development of novel, effective solutions for diabetes management.
Key Market Players
Abbott Laboratories
Dexcom Inc.
Eli Lilly and Company
Enteris BioPharma Inc. (Swk Holdings Corporation)
GlySens Incorporated
MannKind Corporation
Medtronic plc
Sanofi S.A.
Senseonics, Holdings
Report Scope:
In this report, the Global Next Generation Diabetes Therapy and Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Next Generation Diabetes Therapy and Drug Delivery Market.
Available Customizations:
Global Next Generation Diabetes Therapy and Drug Delivery market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
The global market for next-generation diabetes therapy and drug delivery is undergoing rapid expansion. Several factors contribute to this growth, including a rising global incidence of diabetes, technological advancements, and increased awareness about the importance of diabetes management. One of the key drivers of innovation in diabetes therapy and drug delivery is the advancement of technology. Continuous glucose monitoring (CGM) systems, insulin pumps, and smart insulin pens are some examples of cutting-edge technologies that have revolutionized the way patients manage their diabetes. These devices provide real-time data and automate insulin delivery, improving precision and convenience.
Key Market Drivers
Growing Diabetes Epidemic is Driving the Global Next Generation Diabetes Therapy and Drug Delivery Market
The global diabetes epidemic is a major public health concern, affecting individuals of all ages and backgrounds. According to the International Diabetes Federation (IDF), in 2019, there were approximately 463 million adults living with diabetes, and this number is projected to rise to 700 million by 2045 if current trends persist. The majority of diabetes cases are of the type 2 variety, which is closely linked to lifestyle factors such as poor diet and physical inactivity. The impact of diabetes goes beyond health concerns, as it places a significant economic burden on healthcare systems. Diabetes-related medical expenses and lost productivity have a substantial economic cost, both on a global and individual scale. Recognizing the dire need for more effective and patient-friendly treatments, the Next Generation Diabetes Therapy and Drug Delivery market has witnessed significant growth. Innovations in this field aim to address the unique challenges faced by people with diabetes, ultimately leading to better disease management and improved quality of life.
Traditional insulin injections are often inconvenient and painful for individuals with diabetes. The development of advanced insulin delivery systems, such as insulin pumps and continuous glucose monitoring devices, has revolutionized diabetes management. These devices offer precise insulin delivery, reduce the risk of hypoglycemia, and provide real-time glucose monitoring, thus improving overall glycemic control. Researchers have been working on developing an oral insulin delivery method, which would eliminate the need for injections. This technology has the potential to significantly improve patient adherence to treatment regimens. The concept of an artificial pancreas is a game-changer in diabetes therapy. It combines continuous glucose monitoring with automated insulin delivery, creating a closed-loop system that can respond to fluctuations in blood glucose levels in real-time. Such innovations offer the promise of better blood sugar control and fewer diabetes-related complications. Advances in genomics and personalized medicine have enabled the development of diabetes treatments tailored to an individual's genetic makeup. These treatments may prove to be more effective and have fewer side effects than traditional therapies. Telemedicine and digital health solutions have become integral in diabetes management. They provide remote monitoring and support, allowing healthcare professionals to track patients' progress and adjust treatment plans as necessary.
The global Next Generation Diabetes Therapy and Drug Delivery market is expected to grow significantly in the coming years. Factors such as the increasing prevalence of diabetes, the need for more patient-friendly treatment options, and ongoing research and development in the field of diabetes management contribute to this growth. The market is also likely to witness collaborations between pharmaceutical companies, medical device manufacturers, and digital health companies to offer comprehensive solutions for diabetes care. Furthermore, regulatory bodies around the world are increasingly supportive of innovation in diabetes management, streamlining the approval process for new therapies and devices. This has created a favorable environment for companies seeking to bring new products to the market.
Rising Healthcare Expenditure is Driving the Global Next Generation Diabetes Therapy and Drug Delivery Market
The rising healthcare expenditure worldwide, coupled with the growing prevalence of diabetes, has created a strong impetus for the development and adoption of next-generation diabetes therapy and drug delivery solutions. These innovative approaches offer the potential to reduce the economic and human toll of diabetes, improve patient outcomes, and enhance the sustainability of healthcare systems. As research and development in this field continue to progress, the future holds promise for individuals living with diabetes and those dedicated to providing them with the best care possible.
The growth of the global next generation diabetes therapy and drug delivery market is closely tied to the increasing healthcare expenditure seen in many countries. As the number of people living with diabetes continues to grow, healthcare systems are under increasing pressure to provide effective and cost-efficient solutions. Investing in next-generation therapies and drug delivery systems is seen as a way to address this challenge. Diabetes imposes a significant economic burden on both individuals and healthcare systems. The cost of treating diabetes-related complications, hospitalizations, and medications is substantial. Innovations in diabetes management can help reduce these costs and improve overall healthcare sustainability. The shift towards patient-centered care and the demand for improved quality of life has led to the development of next-generation therapies that focus on patient convenience, adherence, and outcomes. Advances in medical technology, data analytics, and artificial intelligence are driving the development of innovative solutions in diabetes management. These technologies not only improve patient care but also contribute to healthcare system efficiency.
Key Market Challenges
Regulatory and Approval Processes
One of the primary challenges in the global diabetes therapy market is the stringent regulatory environment. Developing new therapies and drug delivery methods requires extensive testing, clinical trials, and rigorous safety and efficacy assessments. Obtaining regulatory approval can be a long and costly process, often taking years. This can discourage smaller companies with innovative solutions from entering the market, as they may not have the resources to navigate the regulatory hurdles effectively.
Cost of Innovation
Innovation in diabetes therapy and drug delivery comes at a high cost. Developing and testing new technologies, medications, and delivery methods requires substantial investments in research and development. Many innovative therapies and drug delivery systems remain out of reach for patients due to their high price points. This cost can be a significant barrier to access for individuals with diabetes, particularly in low-income and underprivileged regions.
Patient Adherence
Patient adherence to diabetes therapies and drug delivery methods is a persistent challenge. Even with the introduction of innovative options, patients may struggle to follow their treatment regimens. This non-adherence can lead to suboptimal health outcomes and increased healthcare costs. There is a need for greater patient education, support, and user-friendly therapies to enhance adherence.
Integration of Digital Health Solutions
The integration of digital health solutions and technology into diabetes therapy and drug delivery is a promising avenue, but it comes with its own set of challenges. Ensuring data privacy and security while using apps, wearable devices, and telehealth platforms is critical. Additionally, not all patients have access to smartphones or the internet, potentially leaving some individuals with diabetes at a disadvantage.
Tailoring Therapies to Individual Needs
Diabetes is a highly individualized condition. What works for one patient may not work for another. Personalized medicine has the potential to revolutionize diabetes management, but developing tailored therapies and drug delivery methods can be complex and costly. It requires a deep understanding of a patient's genetic, metabolic, and lifestyle factors, which is not always feasible in routine clinical practice.
Global Disparities
Access to next-generation diabetes therapies and drug delivery methods is not evenly distributed around the world. High-income countries often have better access to cutting-edge treatments, while low and middle-income nations may face limited resources and infrastructure. Addressing these global disparities is a significant challenge in ensuring equitable diabetes care.
Competition and Market Saturation
As the global diabetes therapy and drug delivery market becomes more competitive, companies must continually innovate to stay ahead. However, the market may become saturated with similar products, making it difficult for newcomers to gain a foothold. Additionally, competitive pricing can lead to price wars that negatively impact profit margins.
Key Market Trends
Technological Advancements
Diabetes has emerged as a global health crisis, affecting millions of people worldwide. As the prevalence of diabetes continues to rise, so does the demand for innovative and effective treatments. Technological advancements are playing a pivotal role in shaping the next generation of diabetes therapy and drug delivery solutions, driving the growth of the global diabetes market. Continuous Glucose Monitoring (CGM) Systems have revolutionized diabetes management by providing real-time glucose level data. These devices, often paired with smartphone apps, enable patients and healthcare providers to monitor and adjust insulin levels more accurately. The development of smaller, more comfortable sensors and improved data accuracy has made CGM a game-changer in diabetes therapy. Artificial pancreas systems, also known as closed-loop systems, combine CGM technology with insulin pumps. These devices automatically adjust insulin delivery based on real-time glucose data, reducing the burden on patients and improving blood sugar control. The FDA's approval of such systems has further advanced the adoption of this technology. Traditional insulin pens and pumps have evolved into smart, connected devices that track insulin doses and provide reminders for patients. They allow healthcare providers to remotely monitor and adjust insulin regimens, enhancing patient care and compliance.
Smartphone apps and digital platforms provide patients with tools for tracking their glucose levels, medications, and dietary habits. These platforms also offer educational resources and connect patients with healthcare professionals, promoting self-management and facilitating more personalized treatment plans. Technological advancements have also led to the development of innovative drug delivery systems, such as inhalable insulin and smart patches. These solutions aim to improve the ease of insulin administration and reduce the stigma associated with diabetes treatment.
The convergence of these technological advancements has resulted in a booming market for next-generation diabetes therapy and drug delivery solutions. The global diabetes care devices market was valued at approximately $20 billion in 2020 and is expected to experience robust growth in the coming years. This growth is driven by the increasing prevalence of diabetes, rising patient awareness, and the demand for more convenient and efficient treatment options. Moreover, ongoing research and development in the field of diabetes technology are fueling innovation. Pharmaceutical and medical device companies are investing heavily in improving existing technologies and developing new solutions, which further propel the market's expansion.
Segmental Insights
Product Type Insights
Based on the category of Product Type, CGM Systems emerged as the dominant player in the global market for Next Generation Diabetes Therapy and Drug Delivery in 2022 Continuous Glucose Monitoring (CGM) systems are at the forefront of the next generation of diabetes therapy and drug delivery. These systems use tiny sensors inserted under the skin to measure glucose levels in the interstitial fluid continuously. The data collected is transmitted wirelessly to a receiver or smartphone, providing real-time glucose information, trends, and alerts. CGM systems offer immediate feedback on glucose levels, allowing individuals with diabetes to make informed decisions about their food intake, insulin dosages, and lifestyle choices. CGM systems help individuals maintain target glucose levels, reducing the risk of hypoglycemia and hyperglycemia, which can have severe consequences. These systems provide valuable insights into a person's unique glucose patterns, enabling healthcare professionals to create tailored treatment plans. CGM systems reduce the need for frequent fingerstick tests and simplify the diabetes management process, leading to a better quality of life for patients. CGM technology has continued to evolve, with each new generation of devices becoming more accurate, comfortable, and user-friendly. As these systems become more sophisticated, they offer more than just glucose data. Some CGM devices now provide predictive algorithms and even insulin dosing recommendations.
End user Insights
The Diagnostic/Clinics segment is projected to experience rapid growth during the forecast period. The diagnostic/clinics segment encompasses a wide range of services and tools designed to improve the diagnosis of diabetes and its complications. Early diagnosis is crucial in effective diabetes management, and the segment offers advanced screening tests, point-of-care diagnostics, and genetic testing, aiding in the timely identification of the condition. Clinics equipped with the latest diagnostic technologies can provide a more personalized approach to diabetes management. With the help of advanced diagnostics, healthcare professionals can tailor treatment plans to individual patients, resulting in better glycemic control and patient satisfaction.
Regional Insights
North America emerged as the dominant player in the global Next Generation Diabetes Therapy and Drug Delivery market in 2022, holding the largest market share in terms of value. North America boasts a well-established pharmaceutical and biotechnology sector, with numerous companies dedicated to diabetes research. Leading players, such as Eli Lilly, Novo Nordisk, and Johnson & Johnson, have their headquarters or major operations in the United States. This concentration of industry giants ensures a continuous stream of innovation and investment in diabetes care. North American institutions and universities conduct groundbreaking research in the field of diabetes, which often leads to the development of innovative therapies and drug delivery systems. Collaborations between academia and the private sector are commonplace, facilitating the translation of research findings into practical solutions. The regulatory framework in North America is stringent, ensuring that new therapies and drug delivery methods meet the highest safety and efficacy standards. This environment encourages the development of novel, effective solutions for diabetes management.
Key Market Players
Abbott Laboratories
Dexcom Inc.
Eli Lilly and Company
Enteris BioPharma Inc. (Swk Holdings Corporation)
GlySens Incorporated
MannKind Corporation
Medtronic plc
Sanofi S.A.
Senseonics, Holdings
Report Scope:
In this report, the Global Next Generation Diabetes Therapy and Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Next Generation Diabetes Therapy and Drug Delivery Market, By Product Type:
- Inhalable Insulin
- Oral Insulin
- Insulin Patches
- CGM Systems
- Artificial Pancreas
- Next Generation Diabetes Therapy and Drug Delivery Market, By Indication:
- Type 1 diabetes
- Type 2 diabetes
- Next Generation Diabetes Therapy and Drug Delivery Market, By End user:
- Diagnostic/Clinics
- Intensive Care Units (ICUs)
- Home Healthcare
- Next Generation Diabetes Therapy and Drug Delivery Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Next Generation Diabetes Therapy and Drug Delivery Market.
Available Customizations:
Global Next Generation Diabetes Therapy and Drug Delivery market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas)
4.2.2. By Indication (Type 1 diabetes, Type 2 diabetes)
4.2.3. By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare)
4.2.4. By Region
4.2.5. By Company (2022)
4.3. Market Map
4.3.1. By Product Type
4.3.2. By Indication
4.3.3. By End user
4.3.4. By Region
5. ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type
5.2.2. By Indication
5.2.3. By End user
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Product Type
5.3.1.2.2. By Indication
5.3.1.2.3. By End user
5.3.2. India Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Product Type
5.3.2.2.2. By Indication
5.3.2.2.3. By End user
5.3.3. Australia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Product Type
5.3.3.2.2. By Indication
5.3.3.2.3. By End user
5.3.4. Japan Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Product Type
5.3.4.2.2. By Indication
5.3.4.2.3. By End user
5.3.5. South Korea Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Product Type
5.3.5.2.2. By Indication
5.3.5.2.3. By End user
6. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Indication
6.2.3. By End user
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Indication
6.3.1.2.3. By End user
6.3.2. Germany Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Indication
6.3.2.2.3. By End user
6.3.3. Spain Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Indication
6.3.3.2.3. By End user
6.3.4. Italy Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Product Type
6.3.4.2.2. By Indication
6.3.4.2.3. By End user
6.3.5. United Kingdom Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Product Type
6.3.5.2.2. By Indication
6.3.5.2.3. By End user
7. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Indication
7.2.3. By End user
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Indication
7.3.1.2.3. By End user
7.3.2. Mexico Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Indication
7.3.2.2.3. By End user
7.3.3. Canada Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Indication
7.3.3.2.3. By End user
8. SOUTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Indication
8.2.3. By End user
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Indication
8.3.1.2.3. By End user
8.3.2. Argentina Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Indication
8.3.2.2.3. By End user
8.3.3. Colombia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Indication
8.3.3.2.3. By End user
9. MIDDLE EAST AND AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Indication
9.2.3. By End user
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Indication
9.3.1.2.3. By End user
9.3.2. Saudi Arabia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Indication
9.3.2.2.3. By End user
9.3.3. UAE Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Indication
9.3.3.2.3. By End user
9.3.4. Egypt Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Product Type
9.3.4.2.2. By Indication
9.3.4.2.3. By End user
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET: SWOT ANALYSIS
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. COMPETITIVE LANDSCAPE
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Product & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Dexcom Inc.
14.3. Eli Lilly and Company
14.4. Enteris BioPharma Inc. (Swk Holdings Corporation)
14.5. GlySens Incorporated
14.6. MannKind Corporation
14.7. Medtronic plc
14.8. Sanofi S.A.
14.9. Senseonics, Holdings
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas)
4.2.2. By Indication (Type 1 diabetes, Type 2 diabetes)
4.2.3. By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare)
4.2.4. By Region
4.2.5. By Company (2022)
4.3. Market Map
4.3.1. By Product Type
4.3.2. By Indication
4.3.3. By End user
4.3.4. By Region
5. ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type
5.2.2. By Indication
5.2.3. By End user
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Product Type
5.3.1.2.2. By Indication
5.3.1.2.3. By End user
5.3.2. India Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Product Type
5.3.2.2.2. By Indication
5.3.2.2.3. By End user
5.3.3. Australia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Product Type
5.3.3.2.2. By Indication
5.3.3.2.3. By End user
5.3.4. Japan Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Product Type
5.3.4.2.2. By Indication
5.3.4.2.3. By End user
5.3.5. South Korea Next Generation Diabetes Therapy and Drug Delivery Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Product Type
5.3.5.2.2. By Indication
5.3.5.2.3. By End user
6. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Indication
6.2.3. By End user
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Indication
6.3.1.2.3. By End user
6.3.2. Germany Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Indication
6.3.2.2.3. By End user
6.3.3. Spain Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Indication
6.3.3.2.3. By End user
6.3.4. Italy Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Product Type
6.3.4.2.2. By Indication
6.3.4.2.3. By End user
6.3.5. United Kingdom Next Generation Diabetes Therapy and Drug Delivery Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Product Type
6.3.5.2.2. By Indication
6.3.5.2.3. By End user
7. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Indication
7.2.3. By End user
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Indication
7.3.1.2.3. By End user
7.3.2. Mexico Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Indication
7.3.2.2.3. By End user
7.3.3. Canada Next Generation Diabetes Therapy and Drug Delivery Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Indication
7.3.3.2.3. By End user
8. SOUTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Indication
8.2.3. By End user
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Indication
8.3.1.2.3. By End user
8.3.2. Argentina Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Indication
8.3.2.2.3. By End user
8.3.3. Colombia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Indication
8.3.3.2.3. By End user
9. MIDDLE EAST AND AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Indication
9.2.3. By End user
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Indication
9.3.1.2.3. By End user
9.3.2. Saudi Arabia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Indication
9.3.2.2.3. By End user
9.3.3. UAE Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Indication
9.3.3.2.3. By End user
9.3.4. Egypt Next Generation Diabetes Therapy and Drug Delivery Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Product Type
9.3.4.2.2. By Indication
9.3.4.2.3. By End user
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET: SWOT ANALYSIS
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. COMPETITIVE LANDSCAPE
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Product & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Dexcom Inc.
14.3. Eli Lilly and Company
14.4. Enteris BioPharma Inc. (Swk Holdings Corporation)
14.5. GlySens Incorporated
14.6. MannKind Corporation
14.7. Medtronic plc
14.8. Sanofi S.A.
14.9. Senseonics, Holdings
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
